161 results on '"Jensen, Maj-Britt"'
Search Results
2. Figure S3 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
3. Figure S3 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
4. Table S3 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
5. Figure S5 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
6. Figure S5 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
7. Table S4 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
8. Figure S4 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
9. Data from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
10. Table S2 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
11. Table S1 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
12. Table S1 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
13. Figure S2 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
14. Figure S1 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
15. Data from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
16. Table S3 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
17. Figure S4 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
18. Table S2 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
19. Table S4 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
20. Figure S1 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
21. Table S5 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
22. Table S5 from Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
23. Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer
24. Prognostic Value of Pre-treatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer
25. Evaluation of tumor-infiltrating lymphocytes, PD-L1, and PIK3CA mutations and association with prognosis in HER2-positive early stage breast cancer
26. High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
27. Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors
28. Predictive Biomarkers and Translational Cancer Medicine
29. Real-world survival of Danish patients with HER2-positive metastatic breast cancer
30. Response to van cauwenberge, Borremans, Van Houdt, et al
31. Identifying recurrent breast cancer patients in national health registries using machine learning
32. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
33. A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients
34. A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark
35. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
36. Response to Pederson et al. and Chlebowski et al.
37. Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial
38. Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study
39. Survival in Women Diagnosed With Breast Cancer During Pregnancy
40. Abstract OT2-30-01: Nordictrip, a translational randomized phase-3study exploring the effect of the addition of capecitabine to carboplatinum-based chemotherapy in early “triple negative” breast cancer, ClinicalTrials.gov Identifier: NCT04335669
41. Use of beta‐blockers and risk of contralateral breast cancer
42. First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG
43. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer
44. Predictive Biomarkers and Translational Cancer Medicine
45. Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women
46. Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status
47. The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
48. Vaginal Estrogens in Postmenopausal Women Treated for Early Breast Cancer. An Observational Cohort Study
49. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG)
50. Radiation-induced risk of ischemic heart disease following breast cancer radiotherapy in Denmark, 1977–2005
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.